The Filing Desk

OptimizeRx vs SOPHiA GENETICS

OptimizeRx OPRX · SOPHiA GENETICS SOPH · Health Care Technology

OptimizeRx reported revenue of $109 million in fiscal 2025, 1.4 times SOPHiA GENETICS's $77 million in fiscal 2025. OptimizeRx's revenue grew 18.8% in its latest year, and SOPHiA GENETICS's grew 18.6%. OptimizeRx had an operating margin of 10.7%, against -91.8% at SOPHiA GENETICS. Free cash flow was $19 million at OptimizeRx and −$36 million at SOPHiA GENETICS.

Side by side

OptimizeRxSOPHiA GENETICS
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$109M$77M
Revenue growth18.8%18.6%
Revenue growth a year, last 5 years20.4%22.2%
Gross margin67.2%67.4%
Operating margin10.7%−91.8%
Net margin4.7%−102.2%
Free cash flow$19M−$36M
Free cash flow margin17.1%−47.2%
Return on capital6.4%−207.1%
Net debt to EBITDA0.2x—
Dividends and buybacks$0M$0M
Change in diluted share count3.9%2.2%
Last close$7.01$6.68
P/E at the last close28.0×—
Insider trades, last 12 monthssold $18,752bought $99,000, sold $4.2 million
Piotroski F-score8 of 92 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
OptimizeRxSOPHiA GENETICS
Operating margin
Percent of revenue
OptimizeRxSOPHiA GENETICS
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
OptimizeRxSOPHiA GENETICS

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the OptimizeRx and SOPHiA GENETICS pages.